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Abstract: Chronic kidney disease (CKD) patients are at an increased risk of cardiovascular complications and plasma 
leptin level is elevated in cardio renal syndrome. We wanted to explore leptin levels in patients with different stages of 
CKD and find its association with risk of cardiovascular disease. This cross-sectional study was conducted in 
Nephrology Department of Jinnah Post Graduate Medical Centre (JPMC) from January 2014 to September 2014. Group 
I comprised of controls (GFR=116±8.3, n = 44) acquired from general population, CKD patients were grouped as II, III 
and IV respectively with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n=42) and 20.22±8.4 (n = 42).CKD patients with any 
inflammatory disease, Diabetes Mellitus and on steroid therapy were excluded. Serum leptin, lipid profile and C reactive 
proteins (CRP) were measured. Leptin and CRP levels increased significantly with progression of CKD. High density 
lipoproteins (HDL) to low density lipoproteins (LDL) ratio was significantly high in control as compared to CKD groups 
(p<0.001). A positive correlation of leptin was observed with CRP and HDL/LDL ratio (r= 0.994,p<0.001 and r= 
-0.403p<0.001) respectively. Hyperleptinemia observed with progression of CKD contributed to pathogenesis of 
cardiovascular disease by decreasing HDL/LDL ratio. 
 




End-stage renal disease (ESRD) is a complication of 
impaired renal function and chronic kidney disease 
(CKD) associated with increased morbidity, mortality, and 
increases the risk of cardiac disease (CVD).The 
prevalence of CKD is high in Pakistani population, since 
incidence of hypertension and diabetes in our inhabitants 
is one of the highest in the world. 
 
CKD is linked to a series of multiple toxic physiological 
and metabolic functions. Diabetes and hypertension as 
being its complication are concomitant with lethal 
outcomes. An increased risk of CVD in these patients can 
lead to mortality(Locatelli et al., 2003) which is attributed 
to inflammatory and oxidative stress, erythropoietin(EPO) 
resistance leading to anemia(Kazory and Ross 2009), 
vitamin D deficiency (Levin and Li 2005) and vascular 
calcification (Mizobuchi et al., 2009). Adipocytokines 
such as leptin, are also potentially involved in the 
pathogenesis of metabolic syndrome (e.g. dyslipidemia) 
in End-stage renal disease (Mak and Cheung 2007). 
 
Leptin is an adipose tissue-derived hormone that has been 
associated to numerous metabolic and inflammatory 
factors involved in the pathogenesis of hypertension and 
cardiovascular disease (Wannamethee et al., 2007). 
Increased leptin levels are in response to high energy 
deposition in the form of adipocytes and obesity, 
irrespective of the degree of BMI (Fatima et al., 2013).In 
renal disease the scenario is much different, as the 
initially CKD may be altered with change in grades of 
obesity; and therefore increasing leptin levels and 
resistance (fig. 1). Hyperleptinemia is observed in patients 
during CKD progression and potentially anorexic-
cachectic syndrome. However, histological changes in the 
basement membrane from initial to end stage disease may 
also contribute to the decreased levels of leptin at the end 
stage of CKD (Becker et al., 2005). Leptin is known to be 
important in the regulation of food desire, body 
composition and might also be responsible for metabolic 
changes during CKD leading to inflammation and loss of 
lean body mass (Mak et al., 2006). 
 
[SF1] 
Fig. 1: This diagram shows the illustration of the 
hypothetical mechanism of etiology of Chronic Kidney 
Disease. 
 
The etiology of kidney dysfunction may initially be 
associated with long-standing obesity and insulin 
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resistance, like the metabolic syndrome (MetS). Leptin is 
predominantly washed out from the circulation by the 
kidneys after the metabolic degradation in the renal 
tubules (Cumin et al., 1996). Shamsuzzaman et al. 
(Shamsuzzaman et al., 2004) established an association 
between serum levels of leptin and C-reactive protein 
(CRP) in healthy young adults. Leptin plays a role in 
stimulating the sympathetic system of the body leading to 
elevated blood pressure and deranged GFR(Carlyle et al., 
2002 including natriuresis (Jackson and Li 1997)to 
maintain the electrolyte homeostasis (Hall et al., 1990). 
The reduced clearance of plasma leptin leads to high 
levels of circulating leptin probably due to feedback-loop 
that down regulates certain genes in hyperleptinemic 
patients having advanced CKD (Nordfors et al., 1998).  
 
Increased adiposity (measured in reference to BMI) is 
associated with increased serum leptin levels as it is 
recognized to proportional to obesity. The oxidative stress 
caused by the activation of reactive oxygen specie (ROS) 
during the sub clinical inflammatory condition during 
obesity, leads to the damage of the podocytes thus leading 
to advanced CKD (Sharma et al., 2008). 
 
The objective of the study was to explore leptin levels in 
patients with different stages of ESRD and find its 
association with metabolic dysfunction in CKD patients. 
With the agreement that obesity and hyperleptinemia both 
cause metabolic dysfunction in CKD patients, we selected 
patients with normal BMI and then studied the 
relationship of Leptin, inflammatory marker reactive 
protein and metabolic dysfunction in CKD patients. 
 
MATERIALS AND METHODS 
 
Study participants 
This cross-sectional study was conducted in the 
Department of Biological and Biomedical Sciences 
(BBS), Aga Khan University in collaboration with the 
Nephrology Department of J.P.M.C. during the period of 
January 2014 to September 2014. Two hundred patients 
were recruited for the study out of which 170 subjects 
were enrolled in present study. CKD patients between the 
ages 35- 45 years without any known cardiovascular 
disease were recruited. We excluded the patients with 
Diabetes Mellitus, liver disease, acute or chronic 
inflammatory disease and patient on steroid therapy. Total 
of 170 were divided into four groups as: Group I control 
subjects (GFR=116±8.3, n = 44), recruited from BBS, 
Aga Khan University. Group II, III and IV were CKD 
patients with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n = 
42) and 20.22±8.4 (n = 42), respectively were enrolled 
from Nephrology department of JPMC.  
 
Ethics statement  
The research protocol was approved by the Institutional 
Review Board of the Basic Medical Science Institute, 
Jinnah Postgraduate Medical Centre (NO.F.1-
2/2013/BMSI-E.COMT/003/ JPMC). Written informed 
consents were attained from study subjects and all 
investigations were conducted in accordance with the 
principles expressed in the Declaration of Helsinki. 




At the time of enrollment questionnaire was employed to 
record the baseline demographic and clinical data of the 
study subjects from their medical records. All study 
participants were requested to come with 10-12 hours 
overnight fasting for sample collection. The analysis of 
biochemical parameters including Cholesterol, 
Triglycerides and HDL-c were measured by 
spectrophotometry using commercially available Merck 
kits. Low density lipoprotein (LDL-c) was measure by 
Friedwal’s formula (Friedewald et al., 1972). CRP 
(mg/dl) were determined by Enzyme Linked Immuno-
Sorbent Assay kit method Glomerular filtration rate 
(GFR) was estimated by Cockcroft & Gault 
equation(Cockcroft and Gault 1976). Serum leptin levels 
were measured by commercially available ELISA kits 
method. Serum HDL-cholesterol was determined by kit 
manufactured by Merck, France. LDL-cholesterol was 
calculated according to Friedewald’s formula (Friedewald 
et al., 1972). Triglycerides were determined by using 
Glycerol-3-Phosphate Oxidase Phenol Aminophenanzone 
(GPO-PAP) method, by Merck, France. Serum cholesterol 
was estimated by enzymatic colorimetric (CHOD-PAP) 





In this study SPSS (version 11; SPSS Inc., Chicago, IL, 
USA) was used to statistically analyze the descriptive data 
of continuous variables including age, height, weight, 
BMI and blood pressure along with serum Cholesterol, 
Triglycerides, HDL-C and LDL-c mean ± standard 
deviation (SD). Statistical comparisons were calculated 
using a student t-test and Mann Whitney U test for 
continuous/quantitative variables. Pearson’s coefficient of 
correlation (r) was used for the determination of the 
correlation of GFR levels with and lipid profile. In all 





Total of 170 subjects had mean BMI of 22.32±0.9 
Kg/m2and mean leptin levels 8.26±4.6 ng/ml. Leptin 
levels increased significantly with progression of 
CKD.CRP was significantly increased in CDK groups as 
compared to group I (table 1). In lipid profile, cholesterol, 
triglyceride and LDL were significantly high in CKD 
groups (p<0.001), while HDL was significantly low  
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(p<0.001), as compared to Group I (table 1). The 
HDL/LDL ratio was significantly reduced with 
progression of CKD. A positive correlation was observed 
between leptin and CRP as shown in fig. 2 (r=0.994, 
p<0.001).Correlation of Leptin with HDL/LDL ratio 
showed an inverse correlation r=-0.403 with p<0.001. 
[SF2] 




There have been various studies exploring the serum 
leptin levels in different conditions but none points out it’s 
relation to metabolic dysfunction in CKD Pakistani 
population. To fill this gap we designed this study to 
assess the levels of leptin and CRP in CKD patients. 
 
Generally, high plasma concentrations of cholesterol, 
LDL, and to some extent high total triglyceride 
concentrations with low concentrations of HDL, are 
associated with increased atherosclerotic CVD risk (Kwan 
et al., 2007, Thomas et al., 2008). Same pattern of uremic 
lipid profile has been evident in our CKD population with 
gradual shift towards altered cholesterol, triglyceride and 
HDL. Various elements are concomitant with the 
development of dyslipidemia in chronic renal impairment 
(Kwan et al., 2007). 
 
Inflammation probably plays a key role in the initiation 
and progression of the atherosclerotic process(Ross 
1999). High serum concentrations of systemic 
inflammatory markers such as CRP have been associated 
with atherosclerosis (Stenvinkel et al., 2008).  
 
It has been observed that increased BMI of CKD patients 
mediate link between obesity and CVD by its effects on 
arterial pressure (Menendez et al., 2000), inflammatory 
vascular response (Konstantinides et al., 2001, Bodary et 
al., 2002), and platelet aggregation (Chaldakov et al., 
2001, Cooke and Oka 2002). Several studies advocate that 
adipose tissue releases leptin (Friedman and Halaas 1998) 
which possesses cytokine-like properties which is 
responsible for elevated IL-6 and C reactive proteins. The 
research of ours study highlight the role of Leptin in 
patients of normal BMI. Our study is strengthened by 
other studies in CKD patients where CRP was found to be 
associated with renal disease explained by the reactive 
oxygen specie being activated and causing an 
inflammatory condition. This inflammation under such 
conditions might cause altered lipid profile, thus increase 




Hyperleptinemia in progressive CKD patients of our 
population demonstrated high CRP with low HDL/LDL 
ratio. This association explains the relationship of raised 
Leptin levels and CRP in progression of CKD as well as 






Mean ± SD 
Group II 
(CKD Stage II, 
n = 42) 
Mean ± SD 
Group III 
(CKD Stage III, 
n = 42) 
Mean ± SD 
Group IV 
(CKD Stage IV, 
n = 42) 
Mean ± SD 
p value 
Age (year) 55.73 ± 2.47 54.78±2.54 55.42±3.42 57.56 ±5.49 >0.5 
Weight (kg) 58.7 ± 2.47 62.9±9.7 68.311±9.54 64.9 ± 9.7 <0.5 
Leptin (ng/ml) 2.56±1.3 6.58±1.94* 10.21±1.9°* 13.45±3.05ꜝ <0.001 
CRP (mg/dl) 2.80±0.84 3.2±0.12 3.75±0.56 4.00 ±0.76* <0.001 
Cholesterol (mg/dl) 147.4±12.28 176±5.84 198±9.24 229.86±17.65* <0.001 
Triglycerides (mg/dl) 118.5±11.66 122±9.56 169±8.65 186.7±9.19ꜝ <0.001 
HDL (mg/dl) 41.14±11.86 34.85±6.25 36.12±5.94 30.43±13.5* <0.001 
LDL (mg/dl) 80.21±13.98 101.5±16.52 145±19.23 161.1±12.95ꜝ <0.001 
HDL/LDL ratio 0.7054±0.08 0.5779±0.08 0.46±0.10 0.25±0.03 <0.001 
*significant as compared to controls, p<0.01,°significant as compared to group II, p<0.01, #significant as compared to controls and 
overweight p<0.01,ꜝsignificant as compared to group I, II, III p<0.01 
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metabolic dysregulation that may lead to pathogenesis of 
cardiovascular disease in advanced CKD patients. 
Implication of the study  
Future longitudinal studies are required to explicate the 
possible mechanisms by which leptin causes metabolic 




Becker B, Kronenberg F, Kielstein JT, Haller H, Morath 
C, Ritz E and Fliser D (2005). Renal insulin resistance 
syndrome, adiponectin and cardiovascular events in 
patients with kidney disease: The mild and moderate 
kidney disease study. Journal of the American Society 
of Nephrology, 16(4): 1091-1098. 
Bodary PF, Westrick R J, Wickenheiser K J, Shen Y and 
Eitzman DT (2002). Effect of leptin on arterial 
thrombosis following vascular injury in mice. JAMA, 
287(13): 1706-1709. 
Briffa J F, McAinch A J, Poronnik P and Hryciw DH 
(2013). Adipokines as a link between obesity and 
chronic kidney disease. American Journal of 
Physiology-Renal Physiology, 305(12): F1629-F1636. 
Carlyle M, Jones O B, Kuo JJ and Hall JE (2002). 
Chronic cardiovascular and renal actions of leptin role 
of adrenergic activity. Hypertension, 39(2): 496-501. 
Chaldakov G, Fiore M, Stankulov I, Hristova M, Antonelli 
A, Manni L, Ghenev P, Angelucci F and Aloe L (2001). 
NGF, BDNF, leptin and mast cells in human coronary 
atherosclerosis and metabolic syndrome. Archives of 
Physiology and Biochemistry, 109(4): 357-360. 
Cockcroft D W and Gault MH (1976). Prediction of 
creatinine clearance from serum creatinine. Nephron, 
16(1): 31-41. 
Cooke JP and Oka R K (2002). Does leptin cause vascular 
disease? Circulation, 106(15): 1904-1905. 
Cumin F, Baum H and Levens N (1996). Leptin is cleared 
from the circulation primarily by the kidney. 
International journal of obesity and related metabolic 
disorders: journal of the International Association for 
the Study of Obesity, 20(12): 1120-1126. 
Fatima S S, Bozaoglu K, Rehman R, Alam F and Memon 
AS (2013). Elevated chemerin levels in Pakistani men: 
An interrelation with metabolic syndrome phenotypes. 
PLoS One, 8(2): e57113. 
Friedewald WT, Levy RI and Fredrickson DS (1972). 
Estimation of the concentration of low-density 
lipoprotein cholesterol in plasma, without use of the 
preparative ultracentrifuge. Clinical Chemistry, 18(6): 
499-502. 
Friedman JM and Halaas JL (1998). Leptin and the 
regulation of body weight in mammals. Nature, 
395(6704): 763-770. 
Hall JE, Mizelle HL, Hildebrandt DA and Brands MW 
(1990). Abnormal pressure natriuresis. A cause or a 
consequence of hypertension? Hypertension, 15(6 Pt 
1): 547-559. 
Jackson EK and Li P (1997). Human leptin has natriuretic 
activity in the rat. American Journal of Physiology-
Renal Physiology, 272(3): F333-F338. 
Kazory A and Ross EA (2009). Anemia: the point of 
convergence or divergence for kidney disease and heart 
failure? Journal of the American College of 
Cardiology, 53(8): 639-647. 
Konstantinides S, Schäfer K, Koschnick S and Loskutoff 
DJ (2001). Leptin-dependent platelet aggregation and 
arterial thrombosis suggests a mechanism for 
atherothrombotic disease in obesity. Journal of Clinical 
Investigation, 108(10): 1533. 
Kwan B C, Kronenberg F, Beddhu S and Cheung A K 
(2007). Lipoprotein metabolism and lipid management 
in chronic kidney disease. Journal of the American 
Society of Nephrology, 18(4): 1246-1261. 
Levin A and Li Y C (2005). Vitamin D and its analogues: 
Do they protect against cardiovascular disease in 
patients with kidney disease&quest. Kidney 
international, 68(5): 1973-1981. 
Locatelli F, Pozzoni P, Tentori F and Del Vecchio L 
(2003). Epidemiology of cardiovascular risk in patients 
with chronic kidney disease. Nephrology Dialysis 
Transplantation, 18(suppl 7): vii2-vii9. 
Mak R, Cheung W, Cone R and Marks D (2006). Leptin 
and inflammation-associated cachexia in chronic 
kidney disease. Kidney international, 69(5): 794-797. 
Mak RH and Cheung W (2007). Adipokines and gut 
hormones in end-stage renal disease. Peritoneal 
Dialysis International, 27(Supplement 2): S298-S302. 
Menendez C, Baldelli R, Lage M, Casabiell X, Pinero V, 
Solar J, Dieguez C and Casanueva FF (2000). The in 
vitro secretion of human leptin is gender-dependent but 
independent of the body mass index of the donors. 
European Journal of Endocrinology, 143(5): 711-714. 
Mizobuchi M, Towler D and Slatopolsky E (2009). 
Vascular calcification: The killer of patients with 
chronic kidney disease. Journal of the American 
Society of Nephrology, 20(7): 1453-1464. 
Nordfors L, Lönnqvist F, Heimbürger O, Danielsson A, 
Schalling M and Stenvinkel P (1998). Low leptin gene 
expression and hyperleptinemia in chronic renal 
failure. Kidney International, 54(4): 1267-1275. 
Rifai N and Warnick GR (2006). Lipids, lipoproteins, 
apolipoproteins and other cardiovascular risk factors. 
Tietz textbook of clinical chemistry and molecular 
diagnostics, 26: 903-981. 
Ross R (1999). Atherosclerosis is an inflammatory 
disease. American heart journal, 138(5): S419-S420. 
Shamsuzzaman A S, Winnicki M, Wolk R, Svatikova A, 
Phillips B G, Davison D E, Berger P B and Somers V K 
(2004). Independent association between plasma leptin 
and C-reactive protein in healthy humans. Circulation, 
109(18): 2181-2185. 
Sharma K, RamachandraRao S, Qiu G, Usui H K, Zhu Y, 
Dunn SR, Ouedraogo R, Hough K, McCue P and Chan 
L (2008). Adiponectin regulates albuminuria and 
Sabeela Noor 
Pak. J. Pharm. Sci., Vol.----, No.0, ---------- 20----, pp.000-000 5 
podocyte function in mice. The Journal of Clinical 
Investigation, 118(5): 1645. 
Stenvinkel P, Carrero J J, Axelsson J, Lindholm B, 
Heimbürger O and Massy Z (2008). Emerging 
biomarkers for evaluating cardiovascular risk in the 
chronic kidney disease patient: How do new pieces fit 
into the uremic puzzle? Clinical Journal of the 
American Society of Nephrology, 3(2): 505-521. 
Thomas R, Kanso A and Sedor JR (2008). Chronic kidney 
disease and its complications. Primary care: Clinics in 
office practice, 35(2): 329-344. 
Wannamethee SG, Tchernova J, Whincup P, Lowe GD, 
Kelly A, Rumley A, Wallace AM and Sattar N (2007). 
Plasma leptin: associations with metabolic, 
inflammatory and haemostatic risk factors for 
cardiovascular disease. Atherosclerosis, 191(2): 418-
426. 
 
 
 
